NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News $84.52 +1.59 (+1.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$84.28 -0.24 (-0.28%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About VanEck Pharmaceutical ETF (NASDAQ:PPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PPH alerts:Sign Up Key Stats Today's Range$83.38▼$84.7050-Day Range$82.93▼$91.7852-Week Range$77.67▼$99.51Volume656,218 shsAverage Volume407,707 shsMarket Capitalization$464.01 millionAssets Under Management$497.64 millionDividend Yield2.31%Net Expense Ratio0.36%Aggregate RatingModerate Buy ETF Overview The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck. Read More VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.56%0.56%0.54%0.53%Other Expenses0.01%0.47%0.56%0.52%0.56%Total Expense0.36%0.75%0.76%0.73%0.73%Fee Waiver0.00%-0.67%-0.66%-0.50%-0.63%Net Expense0.36%0.60%0.63%0.63%0.60% Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PPH ETF News HeadlinesJ&J rallies big pharma after earnings despite Trump’s latest tariff threatJuly 16, 2025 | msn.comPPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And CenterJuly 7, 2025 | seekingalpha.com379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsAugust 2 at 2:00 AM | True Market Insiders (Ad)VanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.6069July 1, 2025 | msn.comGlobal pharma stocks down as Trump renews tariff threatJune 17, 2025 | msn.comPPH, Big Pharma Stocks Volatile on Trump Drug PricingMay 14, 2025 | finance.yahoo.comSee More Headlines PPH ETF - Frequently Asked Questions How have PPH shares performed this year? VanEck Pharmaceutical ETF's stock was trading at $86.28 on January 1st, 2025. Since then, PPH shares have decreased by 2.0% and is now trading at $84.52. Who are VanEck Pharmaceutical ETF's major shareholders? Top institutional shareholders of VanEck Pharmaceutical ETF include J.Safra Asset Management Corp (4.77%), Adamsbrown Wealth Consultants LLC (2.82%), Prime Capital Investment Advisors LLC (1.73%) and Phoenix Financial Ltd. (1.08%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Pharmaceutical ETF investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMVIS US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings25 Fund Statistics Assets Under Management$476.06 million Average Daily Volume$482.43 thousand Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume5,898 Put Options5,889 Call Options9 Short Interest2,570,000 shs Miscellaneous Outstanding Shares5,490,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 10 PPH HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 18.81%Johnson & Johnson (NYSE:JNJ)Holding Weight: 10.92%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 7.60%Novartis AG ADRHolding Weight: 7.25%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 6.10%Pfizer (NYSE:PFE)Holding Weight: 4.70%Sanofi (NASDAQ:SNY)Holding Weight: 4.58%AstraZeneca (NASDAQ:AZN)Holding Weight: 4.54%AbbVie (NYSE:ABBV)Holding Weight: 4.52%McKesson (NYSE:MCK)Holding Weight: 4.49%Full Holdings DetailsPPH Sector ExposurePPH Industry Exposure This page (NASDAQ:PPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
